Mohamed Abdulla

metastatic colorectal cancer chemotherapy immunotherapy prostate cancer angiogenesis crpc bevacizumab colorectal cancer enzalutamide gastric cancer colon cancer adjuvant denosumab breast cancer abiraterone acetate ramucirumab rectal cancer neoadjuvant radiation therapy cetuximab bone metastases parp inhibitors guidelines metastatic colon cancer molecular subtypes sidedness regorafinib cinv metastatic prostate cancer pd1 total neoadjuvant anti-egfr therapy docetaxel cabazitaxel targeted therapy castrate resistant avoid surgery in rectal cancer androgen deprivation therapy bone health mtor inhibitors everolimus cancer aflibercept. anti-angiogenic therapy panitumumab metastatic zoladronic acid advanced important 2023 brca mutation metastatic disease triple negative ovarian cancer long acting somatostatin receptor analogues neuroendocrine tumors olaparib platinum sensitivity and resistance cjemoresistant chemosensitive high grade serous cancer ovary tas 102 nonmetastatic apaultamide achievements aims of treatment strategy basic principles cancer management treatment sequence pathophysiology sensitive apalutamide hspc enhanced survival treatment 1ry tumor location short course long course concurrent therapy disease stabilizaton non crc crc msi h vegf egfr left colon right colon adt mhspc ctla4 pd/l1 checkpoint inhibitors subsequent treatment lines in mcrc 3rd line treatment vomiting and chemotherapy nausea and chemotherapy tumor location right versus left colon cancer first line advanced and metastatic her2neu androgen receptor and biosynthesis biology lhrh rankl inhibitors bone cancer pd-l1 ctl4 ngs mmr anti-pd- 1 directed therapy. msi pazobanip nivolumam cabozantinibnib tki mtor renal cell carcinoma neoadjuvant therapy pcr adjuvant therapy watch and wait database near total neoadjuvant pitfalls solution and management problems liver limited disease of colorectal cancer origin medical management prostatectomy updates asco gi 2017 molecular sutying trastusumab early tumor shrinkage urology debates updates in urology mcrc mdt management abiraterone hormonal therapy oligometasdtases cancer minded basic knowledge bone physiology giant cell tumor of bones target therapy molecular basis genetic signature sequencing updates asco gi 2016 circumfrential resection margins chemoradiation targeted therapies molecular background skeletal related events sre bisphosphonates gastric andti-egfr anti-vegf liver metastases skeletal related events economic burden updated informations - evidence based medicine brain metastases. rapid arc brain radiosurgery rcc neuroendocrine sunitinib tme rectal angiogensis screening anti-angiogenic. anti-epidermal growth factor receptor aflibercept head and neck cancers radiation therapy. cancer breast management of skeletal related events cancer prostate systemic treatment. trastuzumab her 2 neu